{"id":"NCT04167514","sponsor":"CSL Behring","briefTitle":"Treatment of GVHD in Hematopoietic Stem Cell Transplant (HSCT) Recipients Using AAT Plus Corticosteroids (CS) Compared With Corticosteroids Alone","officialTitle":"A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase III Trial of Alpha 1 - Antitrypsin (AAT) Combined With Corticosteroids vs Corticosteroids Alone for the Treatment of High Risk Acute Graft-versus-Host Disease (GVHD) Following Allogeneic Hematopoietic Stem Cell Transplant","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-01-09","primaryCompletion":"2023-09-11","completion":"2024-06-26","firstPosted":"2019-11-19","resultsPosted":"2025-08-29","lastUpdate":"2025-08-29"},"enrollment":136,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Graft Versus Host Disease (GVHD)"],"interventions":[{"type":"BIOLOGICAL","name":"Alpha-1 antitrypsin (AAT)","otherNames":["Alpha-1 proteinase inhibitor (A1-P1)"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"AAT","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"Study CSL964\\_5001 will investigate the efficacy of AAT with corticosteroids compared with corticosteroids alone as first line therapy for patients with high-risk acute GVHD","primaryOutcome":{"measure":"Overall Response Rate (ORR) to Acute Graft-versus-Host Disease (GVHD) Treatment","timeFrame":"At Day 28","effectByArm":[{"arm":"Alpha-1 Antitrypsin (AAT)","deltaMin":60,"sd":null},{"arm":"Placebo","deltaMin":45.1,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.034"}]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":5},"locations":{"siteCount":25,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":11,"n":63},"commonTop":["Hyperglycaemia","Oedema peripheral","Hypomagnesaemia","Hypocalcaemia","Hypertension"]}}